HDFC Bank Limited Common Stock vs Regeneron Pharmaceuticals Inc — how do they compare? HDFC Bank Limited Common Stock trades at $22.21 (market cap $110.31B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B). The key difference: HDFC Bank Limited Common Stock is the larger of the two by market cap, and HDFC Bank Limited Common Stock pays the higher dividend (1.86%). Which is the better fit depends on your goals — on Pluang, investors hold HDFC Bank Limited Common Stock for 0 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| HDB | REGN | |
|---|---|---|
Market Cap | $110.31B | $76.14B |
Volume | 13,548,204 | 500,239 |
Sector | Financials | Health |
52-Week High | $37.18 | $852.03 |
52-Week Low | $21.84 | $557.73 |
Typical Hold Time | 0 Days | 107 Days |
Enterprise Value | $14.19T | $70.85B |
Dividend Yield | 1.86% | 0.51% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HDFC Bank provides retail, wholesale, and treasury banking services in India. Its offerings include deposits, lending, payments, trade finance, and financial services for individuals and businesses.
Read more on HDB →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →